KCNN4 and Alzheimer disease: Due to its demonstrated effects on models of CVD and traumatic brain injuries, two well-known risk factors for AD, KCa3.1 inhibition could offer additional therapeutic benefits for mixed pathologies commonly seen in AD patients.